https://scholars.lib.ntu.edu.tw/handle/123456789/569402
標題: | Simvastatin as a Novel Strategy To Alleviate Periapical Lesions | 作者: | SZE-KWAN LIN SANG-HENG KOK YUAN-LING LEE Hou K.-L. Lin Y.-T. Chen M.-H. Wang C.-C. Hong C.-Y. |
公開日期: | 2009 | 卷: | 35 | 期: | 5 | 起(迄)頁: | 657-662 | 來源出版物: | Journal of Endodontics | 摘要: | Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are widely used cholesterol-lowering agents that also possess anti-inflammatory activities. Cysteine-rich 61 (Cyr61) and CCL2 are potential osteolytic mediators in inflammatory bone diseases. The study assessed the effect of simvastatin on tumor necrosis factor α (TNF- α)--induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. The therapeutic effect of simvastatin on rat apical periodontitis was also examined. The synthesis of Cyr61 in MG-63 was assessed by Western analysis. Expression of CCL2 was examined by an enzyme-linked immunosorbent assay. The effect of simvastatin on induced rat periapical lesion was examined radiographically and immunohistochemically. Western blot showed that TNF-α stimulated Cyr61 synthesis in MG-63, whereas simvastatin attenuated this effect in a dose-dependent manner. Simvastatin also reduced the levels of TNF-α-induced CCL2, and exogenous Cyr61 restored the inhibitory effects. Radiography and histopathology revealed that the administration of simvastatin markedly diminished the severity of induced rat periapical lesions. The numbers of Cyr61-synthesizing osteoblasts and CD-68-positive macrophages were also decreased. Simvastatin suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions. ? 2009 American Association of Endodontists. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-65349102871&doi=10.1016%2fj.joen.2009.02.004&partnerID=40&md5=9db1123ad7e27dd3aa37b1245abfaba9 https://scholars.lib.ntu.edu.tw/handle/123456789/569402 |
ISSN: | 0099-2399 | DOI: | 10.1016/j.joen.2009.02.004 | SDG/關鍵字: | CCL2 protein, human; CD68 antigen, human; CYR61 protein, human; cysteine rich protein 61; differentiation antigen; hydroxymethylglutaryl coenzyme A reductase inhibitor; leukocyte antigen; monocyte chemotactic protein 1; simvastatin; tumor necrosis factor alpha; animal; article; cell count; cell line; chemotaxis; disease course; disease model; dose response; drug antagonism; drug effect; enzyme linked immunosorbent assay; human; immunohistochemistry; macrophage; osteoblast; osteolysis; radiography; rat; Sprague Dawley rat; tooth periapical disease; tooth radiography; Western blotting; Alveolar Bone Loss; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Western; Cell Count; Cell Line; Chemokine CCL2; Chemotaxis; Cysteine-Rich Protein 61; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Macrophages; Osteoblasts; Periapical Periodontitis; Radiography, Dental, Digital; Rats; Rats, Sprague-Dawley; Simvastatin; Tumor Necrosis Factor-alpha |
顯示於: | 臨床牙醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。